Comparison of effects of two treatment schemes in Helicobacter pylori
Grażyna Bała, Grażyna Mierzwa, Mieczysława Czerwionka-Szaflarska, Anna Szaflarska-SzczepanikMed Sci Monit 1999; 5(5): CR885-890 :: ID: 503347
Abstract
The aim of the present work was to compare the efficiency and tolerance of two therapies applied for the treatment of H. pylori infection in children with gastritis and duodenitis and chronic duodenal ulcer disease. 153 test subjects (aged 7-17 years) with gastritis and duodenitis as well as chronic ulcer disease and H.p. infection took part in the study. The children received two different types of therapy.Scheme I (94 children aged 7-12 years): Bismuth citrate (8 mg/kg/day in 4 doses for 6 weeks), Amoxicillin (50 mg/kg/day in 3 doses for 2 weeks), Metronidazole (20 mg/kg/day in 3 doses for 2 weeks). Scheme II (59 children aged 10-17 years, body mass > 35 kg): Pantoprazole (2x40 mg in 2 doses), Clarithromycin (15 mg/kg/day in 2 doses), Metronidazole (20 mg/kg/day in 2 doses) for 7 days. In patients with duodenal ulcer treated according to scheme II, the therapy was continued with 1x40 mg pantoprazole for the following 14 days. Clinical, endoscopic and histological assessment of treatment efficiency was performed. The presence of H.p. infection was determined before and 4-6 weeks after the completion of treatment.
Results: H.p. eradication with the regression of clinical symptoms,macroscopic and histological improvement of mucosa and the healing of duodenal ulcer was obtained in 85% children treated according to scheme I. As far as scheme II is concerned, eradication of H.p. infection together with clinical, macroscopic and histological improvement as well as the healing of ulceration in duodenal bulb was observed in 93% children. Adverse reactions such as headache, nausea, mycosis were recorded only in 2.8% children treated according to scheme I.The comparative analysis performed by our team showed the superiority of scheme II due to its high efficiency in the treatment of duodenal ulcer, large extent of H.p. eradication, good tolerance and short therapy duration.
key words: Helicobacter pylori, children, treatment, pantoprazole,clarithromycin
Keywords: clarithromycin, pantoprazole, treatment, children, Helicobacter pylori
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
26 Feb 2024 : Clinical Research
Predictive Value of Combined HbA1c and Neutrophil-to-Lymphocyte Ratio for Diabetic Peripheral Neuropathy in...Med Sci Monit In Press; DOI: 10.12659/MSM.942509
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952